^
    7d
    Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=805, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Oncotype DX Genomic Prostate Score® Assay • Prolaris®
    10d
    Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy. (PubMed, Eur Urol Oncol)
    GPS integration enhances BCR risk stratification in the RP setting. CAPRA-G and CAPRA-SG scores quantify genomic risk and translate GPS into simple, clinically applicable tools with improved clinical utility. External validation is warranted.
    Journal
    |
    Oncotype DX Genomic Prostate Score® Assay
    26d
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide
    30d
    Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies (clinicaltrials.gov)
    P=N/A, N=241, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jul 2027 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Oncotype DX Genomic Prostate Score® Assay
    2ms
    From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis. (PubMed, Transl Oncol)
    Additionally, the review addresses key genetic alterations implicated in prostate carcinogenesis, including mutations in BRCA1/2, HOXB13, and PTEN deletions, as well as changes in the androgen receptor pathway. By evaluating recent advancements and applications of these biomarkers, this review aims to enhance understanding of their role in improving early diagnosis, prognosis, and personalised management of prostate cancer.
    Review • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • ERG (ETS Transcription Factor ERG) • HOXB13 (Homeobox B13) • PCA3 (Prostate cancer associated 3) • PSAP (Prostatic Acid Phosphatase)
    |
    BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation
    |
    Decipher Prostate Cancer Test • ExoDx™ Prostate (IntelliScore) Test • Oncotype DX Genomic Prostate Score® Assay • SelectMDx
    3ms
    Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates. (PubMed, Prostate)
    In this RP cohort, GPS modestly improved prediction of adverse pathology beyond PSA density and MRI, with clinical utility primarily in favorable intermediate-risk patients, where treatment decisions between active surveillance and definitive therapy are uncertain. These findings suggest selective, risk-adapted application of GPS to guide treatment decision-making. Validation in prospective, diverse cohorts is warranted.
    Journal
    |
    Oncotype DX Genomic Prostate Score® Assay
    3ms
    Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2025 --> Apr 2031 | Trial primary completion date: Dec 2025 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    Oncotype DX Genomic Prostate Score® Assay • Prolaris®
    8ms
    Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Oncotype DX Genomic Prostate Score® Assay • Prolaris®
    12ms
    Tissue-based gene expression testing in localized prostate cancer. (PubMed, Curr Opin Urol)
    Tissue-based genomic tests, such as Decipher, Oncotype DX (GPS), and Prolaris, have emerged as prognostic tools for assessing tumor aggressiveness and metastatic potential. Current evidence supports Decipher's prognostic capabilities with studies demonstrating risk stratification while further research is needed for Prolaris and GPS to solidify their role in PCa risk stratification. These assays are intended to guide therapeutic choices, reducing overtreatment in low-risk cases while identifying high-risk patients who may benefit from more aggressive or definitive intervention. Despite growing clinical adoption, challenges such as cost, disparities in access, and variability in physician utilization still remain. Further prospective studies and randomized trials are required to optimize clinical implementation and validate the long-term impact of genomic testing on PCa outcomes.
    Journal
    |
    Oncotype DX Genomic Prostate Score® Assay • Prolaris®
    1year
    Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies (clinicaltrials.gov)
    P=N/A, N=241, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Oncotype DX Genomic Prostate Score® Assay
    over1year
    Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review. (PubMed, Ann Intern Med)
    Department of Veterans Affairs. (PROSPERO: CRD42022347950).
    Review • Journal
    |
    Oncotype DX Genomic Prostate Score® Assay • Prolaris®
    over1year
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2; Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide